Johanna C. Bendell, MD
Anti–PD-1 inhibitors are effective in treating patients with microsatellite-instability high (MSI-H) colorectal cancer (CRC), with the FDA approving pembrolizumab (Keytruda) and nivolumab (Opdivo) for use in this setting.
, Bendell, a medical oncologist at Sarah Cannon Research Institute, discussed the current and emerging treatment landscape of immunotherapy for patients with CRC.
OncLive: What are some of the immunotherapy advances in CRC?
: We have seen very exciting data for patients with MSI-H CRC. These are patients who have a higher rate of mutations than others. They are very responsive to immunotherapies. In fact, we have seen FDA approvals of pembrolizumab for patients with MSI-H cancers, as well as nivolumab for MSI-H CRC, which shows what the benefit of these agents can be for these patients with CRC.
... to read the full story